Werth Victoria P, Askanase Anca D, Lundberg Ingrid E
Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania.
Medical Research, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.
Int J Womens Dermatol. 2021 Sep 24;7(5Part A):583-587. doi: 10.1016/j.ijwd.2021.09.002. eCollection 2021 Dec.
There have been a number of advances in the clinical and translational understanding of cutaneous lupus and dermatomyositis, which both disproportionately affect women. These advances have involved ongoing collaborations between dermatology and rheumatology that highlight the importance of the skin in these disorders, with improvement in the education of trainees and clinical management of these complex multisystem diseases. In addition, a new disease classification has allowed inclusion of patients with skin-predominant dermatomyositis, frequently associated with systemic findings, in the spectrum of idiopathic inflammatory myopathies. Validated outcome measures allow translational research and facilitate progress toward better and more targeted therapeutics. Clinical trials using disease severity tools, such as the Cutaneous Lupus Erythematosus Area and Severity Index and the Cutaneous Dermatomyositis Disease Area and Severity Index, allow measurement of improvement in the skin. Recent results of phase 2 and 3 trials clearly show that patients will benefit from collaborative interactions and studies between dermatology and rheumatology.
在皮肤型狼疮和皮肌炎的临床及转化研究认识方面已经取得了一些进展，这两种疾病对女性的影响尤为严重。这些进展包括皮肤科和风湿科之间持续的合作，突出了皮肤在这些疾病中的重要性，同时改善了对实习生的培训以及对这些复杂多系统疾病的临床管理。此外，一种新的疾病分类法已将皮肤为主型皮肌炎患者纳入特发性炎性肌病范畴，这类患者常伴有全身症状。经过验证的疗效指标有助于开展转化研究，并推动研发更好、更具针对性的治疗方法。使用疾病严重程度工具（如皮肤型红斑狼疮面积和严重程度指数以及皮肤型皮肌炎疾病面积和严重程度指数）的临床试验能够衡量皮肤状况的改善情况。2期和3期试验的最新结果清楚地表明，患者将从皮肤科和风湿科之间的合作互动及研究中受益。
